Navigation Links
Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
Date:4/7/2011

SAN DIEGO, April 7, 2011 /PRNewswire/ -- Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.

Zacharon, whose sole venture investor is Avalon Ventures, will receive up-front payments and research and development funding under the collaboration to develop drugs against targets that impact lysosomal storage diseases. Zacharon is also eligible under the collaboration for payments for meeting development milestones, plus royalties and sales milestones upon commercialization.

"We are very pleased to be working with Pfizer, which has broad compound development expertise, including in the area of small molecules, which should be quite useful to developing drugs for these orphan diseases," said Robin Jackman, Ph.D., president and CEO of Zacharon. "The collaboration provides validation for the potential that lies in Zacharon's broadly applicable technology platform."

Ed Mascioli, M.D., head of Pfizer's Orphan & Genetic Diseases Unit, said: "Part of Pfizer's Orphan & Genetic Diseases Unit's strategic focus relies on collaborations with companies like Zacharon that have promising technologies to help develop treatments for rare diseases.  Zacharon is an ideal partner, and we look forward to working with them to develop treatments for lysosomal storage diseases."

About Lysosomal Storage Diseases

Lysosomal storage diseases (LSDs) are a group of over 40 inherited disorders typically characterized by a deficiency in one or more enzymes that degrade glycans, the carbohydr
'/>"/>

SOURCE Zacharon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... with Capital Data, Inc. , an independent ... according to TeraMEDICA's executive vice president, Paul Schmelzer. ... TeraMEDICA's TI2m archive solution into its own enterprise ... includes Wisconsin, Minnesota, North Dakota, South Dakota, Iowa, ...
... organization? Any temper tantrums lately? Or an adolescent episode ... maybe just a bit of flagging memory? , ,Given ... time or another, it's easy to begin thinking about ... always wisdomas they age. It's even understandable to want ...
... Watts Wacker, hippie extraordinaire and rock-star futurist, spoke at ... week. I was floored by his insights and had ... Watts offered, along with some R-squared commentary: , ,Watts: ... Paulone of JC's disciplesfinally laid down, there were 200,000 ...
Cached Biology Technology:TeraMEDICA and Capital Data enter into diagnostic imaging agreement 2Aging IT 2Aging IT 3Watts Up 2
(Date:10/16/2014)... at William and Mary,s Virginia Institute of Marine ... the Environmental Protection Agency to identify the streams ... to develop tools to help local governments and ... depends critically on a dataset of tidal-marsh observations ... Only with this historical baseline can today,s researchers ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... brain develops, neurons reach out helter-skelter forming new connections, ... the brain chooses which connections to keep and which ... branches have the most electrical activity—a finding that could ... , The work, published in the April 21 issue ...
... specialized subpopulation of the antibody-producing B cells of the ... kinds of immunity -- innate and acquired, Duke University ... between B-1a and B-1b cells they have uncovered offers ... of vaccines, they said. , B cells are the ...
x...
Cached Biology News:Speak up: Louder neurons form more connections 2Specialized immune-system B cells play double-barreled role 2Specialized immune-system B cells play double-barreled role 3